- Author:
Yuchang DI
1
;
Jiacheng BAI
1
;
Mingzhe CHI
1
;
Weixing FAN
2
;
Xuelian ZHANG
1
Author Information
- Publication Type:Journal Article
- Keywords: EF-G; Mycobacterium smegmatis; clustered regularly interspaced short palindromic repeats interference (CRISPRi); drug resistance; minimal inhibitory concentration (MIC)
- MeSH: Antitubercular Agents/pharmacology*; Bacterial Proteins/metabolism*; Drug Resistance; Mycobacterium smegmatis/metabolism*; Peptide Elongation Factor G/pharmacology*
- From: Chinese Journal of Biotechnology 2022;38(3):1050-1060
- CountryChina
- Language:Chinese
- Abstract: As the only translational factor that plays a critical role in two translational processes (elongation and ribosome regeneration), GTPase elongation factor G (EF-G) is a potential target for antimicrobial agents. Both Mycobacterium smegmatis and Mycobacterium tuberculosis have two EF-G homologous coding genes, MsmEFG1 (MSMEG_1400) and MsmEFG2 (MSMEG_6535), fusA1 (Rv0684) and fusA2 (Rv0120c), respectively. MsmEFG1 (MSMEG_1400) and fusA1 (Rv0684) were identified as essential genes for bacterial growth by gene mutation library and bioinformatic analysis. To investigate the biological function and characteristics of EF-G in mycobacterium, two induced EF-G knockdown strains (Msm-ΔEFG1(KD) and Msm-ΔEFG2(KD)) from Mycobacterium smegmatis were constructed by clustered regularly interspaced short palindromic repeats interference (CRISPRi) technique. EF-G2 knockdown had no effect on bacterial growth, while EF-G1 knockdown significantly retarded the growth of mycobacterium, weakened the film-forming ability, changed the colony morphology, and increased the length of mycobacterium. It was speculated that EF-G might be involved in the division of bacteria. Minimal inhibitory concentration assay showed that inhibition of EF-G1 expression enhanced the sensitivity of mycobacterium to rifampicin, isoniazid, erythromycin, fucidic acid, capreomycin and other antibacterial agents, suggesting that EF-G1 might be a potential target for screening anti-tuberculosis drugs in the future.